1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.

Voor meer informatie: http://www.quirem.com/

Other news

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

Production of novel diagnostic radionuclides in small medical cyclotrons

Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...

News